Back to Results
First PageMeta Content
Genentech / South San Francisco / California / Novartis / Ranibizumab / Ketotifen / Pharmaceutical sciences / Pharmacology / Pharmaceutical industry


Microsoft Word - Santen_release_SHAMS_final.docx
Add to Reading List

Document Date: 2013-08-06 15:12:49

Open Document

File Size: 77,84 KB

Share Result on Facebook

City

Osaka / NAPA / /

Company

Storz Ophthalmics / Novartis Pharma / Santen Pharmaceutical Co. Ltd. / Genentech Inc. / Santen Inc. / Opko Health / Pascale Communications LLC / /

Continent

Asia / Europe / /

Country

Japan / Pakistan / United States / /

Currency

USD / /

/

Event

Employment Change / /

Facility

Massachusetts General Hospital / Schepen’s Eye Research Institute / University of South Carolina / Dow Medical College / /

IndustryTerm

ophthalmic pharmaceutical / ophthalmic products / prescription ophthalmic pharmaceuticals / prescription pharmaceuticals / /

MedicalCondition

external diseases / /

NaturalFeature

San Francisco Bay / /

Organization

Harvard Medical School / University of South Carolina / Massachusetts General Hospital / Department of Ophthalmology / Schepen’s Eye Research Institute / Dow Medical College in Karachi / /

Person

Aki Tsujimura / Naveed Shams / Yusuf Ali / Allison Potter / Michael Ford / /

/

Position

Vice President of Research and Development / Vice President / President & Chief Medical Officer / Chief Operating Officer / VP of Clinical Affairs / respected scientist / /

Product

Lucentis / Visudyne / Rescula / Zaditor / /

ProvinceOrState

South Carolina / California / /

Technology

drug delivery / drug discovery / ophthalmic products / drug development / ophthalmic / /

URL

www.santeninc.com / /

SocialTag